European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by i
about
Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian populationCholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort studyRed blood cell fatty acid patterns and acute coronary syndrome.Distribution, size, shape, growth potential and extent of abdominal aortic calcified deposits predict mortality in postmenopausal women.Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.Abdominal aortic calcification quantified by the Morphological Atherosclerotic Calcification Distribution (MACD) index is associated with features of the metabolic syndrome.Weak prediction power of the Framingham Risk Score for coronary artery disease in nonagenarians.CXCL1 microspheres: a novel tool to stimulate arteriogenesis.The effect of problem-based learning in patient education after an event of CORONARY heart disease--a randomised study in PRIMARY health care: design and methodology of the COR-PRIM studyUpdate on lipid-lowering therapy and LDL-cholesterol targets.Who should receive a statin these days? Lessons from recent clinical trials.Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management.Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action.Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialAmlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels.Change in calculated cardiovascular risk due to guideline revision: A cross-sectional study in the Netherlands.Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.Effects of phytosterol ester-enriched low-fat milk on serum lipoprotein profile in mildly hypercholesterolaemic patients are not related to dietary cholesterol or saturated fat intake.The effect of a self-management intervention to reduce vascular risk factors in patients with manifestations of vascular diseases.The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway.A nurse-led multidisciplinary intervention to improve cardiovascular disease profile of patients.Social support and change in vascular risk factors in patients with clinical manifestations of vascular diseases.Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease.Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism.The risk of coronary artery disease associated with cigarette smoking and hypercholesterolemia is additionally increased by the presence of the AT1R gene 1166C allele.The M235T polymorphism of the AGT gene modifies the risk of coronary artery disease associated with the presence of hypercholesterolemia.Cardiac disease in the non-cardiac surgical population: effect on survival.Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly.Validation of cardiovascular risk scores in a liver transplant population.The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients.The SCORE risk model applied to recent population surveys in Norway compared to observed mortality in the general population.Psychosocial considerations in the European guidelines for prevention of cardiovascular diseases in clinical practice: Third Joint Task Force.Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study.Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions.Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events
P2860
Q28283856-80BA6146-2720-4FA8-9C45-CA5978B33F9AQ28740349-0FE9C976-5D8D-4E77-A631-CEC88B98143AQ33440563-832228A4-BFBF-48DF-B121-ED995A0EF090Q33743650-B6DE09A6-D9BA-4817-B2F9-993B895909ADQ33745065-EABC39A7-244D-497E-93C8-3550D93CB473Q34106912-3637263D-61B0-4861-9A84-F6EB6779EE29Q34506768-D6756BEC-CC45-4F5C-B548-3730508B841CQ35864800-DA210EF4-2495-4622-9C27-02F1A06516CCQ36483413-9562992B-9D0F-45F3-8A72-F228108261A7Q36549639-5C70AA8D-BA16-42D4-9D21-48E042D4D3BBQ36589344-AF832BBA-B1AD-4079-A474-0BF0B24DAC16Q36702091-5D9AFFAA-7505-406D-B718-008454932697Q36736169-EA8AF3AD-4E06-45D9-8831-88AEE3F4F6C6Q36922930-28F6B344-AAD1-4BEE-96C9-3A5E6242A5F9Q37199330-876AF847-4FED-49D0-848D-CBCA831C8C13Q37280331-E4BDBF96-29CF-4837-B8F1-429921AA9F61Q37682881-4F6B741C-79F3-47E0-A1D5-65CE1DA8C0B1Q38045284-A2777163-9790-4B5A-AA0E-535C39FF112FQ38554099-F0F7609B-A507-4A95-9F65-D7084085D618Q41527291-146844F1-08A1-4D88-93F1-37B3E32D8D48Q42171027-B0BC0199-D776-4F64-BE7E-204AE36B4640Q43067594-06B1A4FF-9AD0-4DB9-8085-7F5913AA8712Q43203834-0F754E16-8AA0-44AD-BE98-1030FA2D3CA6Q44003856-6BD3EDFF-C7E3-4687-B031-D6A9D82B096BQ44246447-B498E95B-663B-4E6F-ABE7-A7D50E86BB37Q44634062-3AF856A3-7E79-4E29-9402-9163158EE1D9Q45076530-E2C3EDF1-7012-4EA9-8E95-CB4E4BF0C1B2Q45992633-2D473234-B73A-41B9-8D79-747F0DC5BDACQ46207567-AEA7CCC5-13C0-48EA-A5CC-13CA532597BFQ46371867-0E0158DF-DBC4-410B-A3C8-C86F9A7AE7A1Q46647400-D141B77A-13AB-4109-9C9C-F2613C595358Q46664344-DF120C6A-E0D2-4539-AF71-3FA4383A05D5Q46737700-8CAA02F7-7CB8-4CB1-9519-2301674C783FQ46961016-BDFD1714-90EE-4763-8E8C-CB1B8EC3E38EQ46982818-AB08BC64-7DFE-4169-A634-D26F47EACCC9Q50789755-8830188F-29E9-429A-B081-10604D5751C8Q50960331-70741A65-7536-461B-8470-CE4BF7616F77Q51472878-CB6E3841-0812-408E-9BA2-94A298D67201Q51692932-622CC599-2095-4AE2-A12A-FEC0B9A181A4Q51932744-1853B6B0-9E54-498F-A5E1-F75371782206
P2860
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by i
description
im April 2004 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована у квітні 2004
@uk
name
European guidelines on cardiov ...... es of eight societies and by i
@en
type
label
European guidelines on cardiov ...... es of eight societies and by i
@en
prefLabel
European guidelines on cardiov ...... es of eight societies and by i
@en
P2093
P50
P1433
P1476
European guidelines on cardiov ...... es of eight societies and by i
@en
P2093
Carlos Brotons
David Wood
Ettore Ambrosioni
Giuseppe Mancia
Ian Graham
José L. Rodicio
Kalevi Pyörälä
Knut Borch-Johnsen
Kristina Orth-Gomér
P304
P356
10.1016/J.ATHEROSCLEROSIS.2004.02.013
P577
2004-04-01T00:00:00Z